Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19029638 | Compounds and Their Use for Treatment of Hemoglobinopathies | January 2025 | July 2025 | Allow | 6 | 1 | 1 | No | No |
| 18968101 | SUBSTITUTED PHENYL OXAZOLONE COMPOUNDS | December 2024 | April 2025 | Allow | 5 | 1 | 0 | No | No |
| 18943269 | NASAL COMPOSITIONS COMPRISING ALCAFTADINE | November 2024 | September 2025 | Abandon | 10 | 2 | 0 | No | No |
| 18914691 | ARYL-1,2,3-TRIAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITION THEREOF AND METHOD FOR TREATMENT OF BREAST CANCER | October 2024 | January 2025 | Allow | 3 | 1 | 0 | No | No |
| 18676679 | POLYMORPHS OF PHENYL PYRROLE AMINOGUANDIUM SALTS | May 2024 | January 2025 | Allow | 8 | 2 | 1 | Yes | No |
| 18663952 | PRMT5 INHIBITORS AND USES THEREOF | May 2024 | February 2025 | Allow | 9 | 1 | 1 | No | No |
| 18646687 | THIOAMIDE DERIVATIVE AND PREPARATION METHOD AND APPLICATION THEREOF | April 2024 | October 2024 | Allow | 6 | 1 | 0 | No | No |
| 18634599 | IMIDAZOTRIAZINE THIOBENZAMIDE DERIVATIVE, AND PREPARATION METHOD AND APPLICATION THEREOF | April 2024 | November 2024 | Allow | 7 | 1 | 0 | No | No |
| 18131183 | LYSYL OXIDASE INHIBITORS FOR TREATING MYELOID MALIGNANCIES | April 2023 | October 2024 | Allow | 18 | 2 | 0 | No | No |
| 18191283 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | March 2023 | February 2026 | Allow | 35 | 1 | 0 | No | No |
| 18187789 | PYRIMID-2-YL-PYRAZOLE COMPOUNDS AS IRAK INHIBITORS | March 2023 | April 2025 | Allow | 24 | 2 | 1 | Yes | No |
| 18182234 | INHIBITORS OF NITRIC OXIDE SYNTHASES (NOS), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | March 2023 | January 2025 | Allow | 23 | 2 | 1 | Yes | No |
| 18042497 | COMBINATION THERAPIES WITH OLIG2 INHIBITORS | February 2023 | February 2026 | Abandon | 36 | 1 | 0 | No | No |
| 18107164 | SOLID FORMS OF A PARP14 INHIBITOR | February 2023 | March 2026 | Abandon | 37 | 0 | 1 | No | No |
| 18161609 | PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | January 2023 | May 2024 | Abandon | 15 | 1 | 0 | No | No |
| 18015592 | COMPOSITIONS COMPRISING GARDOS CHANNEL ANTAGONISTS AND THEIR USES | January 2023 | February 2026 | Abandon | 37 | 0 | 1 | No | No |
| 18014764 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | January 2023 | July 2025 | Allow | 31 | 0 | 0 | No | No |
| 18014664 | COMBINATION OF AN ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | January 2023 | March 2026 | Abandon | 38 | 0 | 1 | No | No |
| 18014178 | ATR INHIBITORS AND USES THEREOF | January 2023 | February 2026 | Abandon | 37 | 1 | 0 | No | No |
| 18013721 | PYRROLIDINE AMIDE DERIVATIVE SALT AND USE THEREOF | December 2022 | January 2026 | Allow | 37 | 1 | 0 | No | No |
| 18145618 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | December 2022 | February 2025 | Allow | 26 | 2 | 1 | No | No |
| 17992961 | CRYSTALLINE FORMS OF SOLVATES OF TRYPTOPHAN DERIVATIVES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | November 2022 | January 2026 | Allow | 37 | 2 | 0 | No | No |
| 17959466 | METHOD AND COMPOSITION FOR MIMICKING BIOLOGICAL BENEFITS OF CALORIC RESTRICTION | October 2022 | November 2025 | Abandon | 38 | 5 | 0 | Yes | No |
| 17906127 | NERVE CELL DEGENERATION INHIBITOR | September 2022 | January 2026 | Abandon | 40 | 1 | 0 | No | No |
| 17897388 | CO-CRYSTALS | August 2022 | October 2024 | Allow | 25 | 2 | 0 | Yes | No |
| 17821500 | POLYMORPHS OF PHENYL PYRROLE AMINOGUANDIUM SALTS | August 2022 | February 2026 | Allow | 42 | 1 | 1 | No | No |
| 17800184 | COMPOUNDS | August 2022 | January 2026 | Abandon | 41 | 0 | 1 | No | No |
| 17816950 | PENTADECANOYLCARNITINE FOR TREATMENT OF CONDITIONS RELATED TO THE QUALITY OF AGING AND LONGEVITY | August 2022 | December 2024 | Allow | 29 | 2 | 1 | No | No |
| 17792249 | COMPOSITIONS COMPRISING AMINO ACIDS FOR PREVENTION AND/OR TREATMENT OF CANCER | July 2022 | January 2026 | Allow | 42 | 1 | 0 | No | No |
| 17860096 | Additive for Food, Drink and Pharmaceutical Products to Improve Health and Well-Being | July 2022 | January 2026 | Abandon | 42 | 1 | 0 | No | No |
| 17857706 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | July 2022 | August 2024 | Allow | 25 | 1 | 1 | Yes | No |
| 17789321 | COMPOUNDS FOR THE TREATMENT OF MYELOFIBROSIS | June 2022 | December 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17846693 | CANNABIDIOL-BASED TOPICAL REMEDY | June 2022 | January 2025 | Abandon | 31 | 2 | 0 | No | No |
| 17843205 | COMPOSITIONS PROVIDING SLOW RELEASE OF CAFFEINE AND BEVERAGES COMPRISING THE SAME | June 2022 | January 2026 | Abandon | 43 | 2 | 1 | No | Yes |
| 17782632 | TREATMENT FOR ACUTE MYELOID LEUKEMIA OR MYELODYSPLASTIC SYNDROME | June 2022 | September 2025 | Allow | 39 | 1 | 0 | No | No |
| 17776040 | ANTIMALARIAL AGENTS | May 2022 | March 2025 | Allow | 34 | 0 | 0 | Yes | No |
| 17740275 | METHOD FOR CONTINUOUSLY PREPARING N,N-BIS(2,2,6,6-TETRAMETHYL-4-PIPERIDYL)-1,6-HEXAMETHYLENEDIAMINE | May 2022 | May 2024 | Allow | 24 | 1 | 0 | No | No |
| 17774662 | Application of Boron Dipyrromethene Derivatives in Anti-Tumor and Anti-Bacterial Therapy | May 2022 | March 2025 | Allow | 35 | 2 | 0 | Yes | No |
| 17772334 | FIVE-MEMBERED HETEROCYCLIC OXOCARBOXYLIC ACID COMPOUND AND MEDICAL USE THEREOF | April 2022 | January 2026 | Abandon | 45 | 1 | 0 | No | No |
| 17755292 | ACID ADDITION SALT OF RORy REGULATOR | April 2022 | November 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17640294 | Androstane Derivatives with Activity as Pure or Predominantly Pure Stimulators of SERCA2a for the Treatment of Heart Failure. | March 2022 | August 2025 | Allow | 41 | 1 | 0 | Yes | No |
| 17625649 | STABLE ORAL COMPOSITION OF CYCLOPHOSPHAMIDE | January 2022 | July 2025 | Allow | 42 | 1 | 0 | No | No |
| 17542830 | METHODS OF MEDICAL TREATMENT WITH SUR1-TRPM4 CHANNEL INHIBITORS | December 2021 | December 2025 | Abandon | 48 | 2 | 0 | No | No |
| 17615363 | 1,3,4-OXADIAZOLE HOMOPHTHALIMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | November 2021 | June 2025 | Allow | 42 | 1 | 0 | Yes | No |
| 17610867 | SUSTAINED-RELEASE MICROGEL OINTMENTS WITH HIGH DRUG LOADING AND PREPARATION METHODS AND USES THEREOF | November 2021 | February 2025 | Allow | 40 | 1 | 0 | No | No |
| 17519922 | Benzoquinoline Inhibitors of Vesicular Monoamine Transporter 2 | November 2021 | April 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17606319 | CATECHOLAMINE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | October 2021 | April 2025 | Allow | 41 | 1 | 0 | No | No |
| 17496433 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | October 2021 | November 2025 | Abandon | 50 | 2 | 0 | No | No |
| 17496276 | Process of Manufacturing a Stable, Ready to Use Infusion Bag for an Oxidation Sensitive Formulation | October 2021 | September 2025 | Abandon | 47 | 1 | 0 | No | No |
| 17602057 | HEXAHYDRO-1H-PYRAZINO[1,2-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | October 2021 | January 2025 | Allow | 40 | 1 | 0 | No | No |
| 17593474 | A DBAIT MOLECULE IN COMBINATION WITH KINASE INHIBITOR FOR THE TREATMENT OF CANCER | September 2021 | August 2025 | Abandon | 47 | 1 | 0 | No | No |
| 17438262 | APPLICATIONS OF IMINOSTILBENE IN TERMS OF PREVENTING AND TREATING CARDIAC CEREBRAL ISCHEMIA/REPERFUSION INJURY | September 2021 | July 2025 | Abandon | 46 | 2 | 0 | No | No |
| 17435276 | METHODS OF TREATING CANCER WITH FARNESYLTRANSFERASE INHIBITORS | August 2021 | March 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17461988 | TREATMENT WITH P2X3 MODULATORS | August 2021 | August 2025 | Allow | 47 | 3 | 0 | Yes | No |
| 17461325 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN | August 2021 | May 2025 | Allow | 44 | 2 | 0 | Yes | No |
| 17045409 | COMPOSITION FOR PREVENTING AND TREATMENT OF STROKE | August 2021 | December 2024 | Abandon | 50 | 1 | 0 | No | No |
| 17430721 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | August 2021 | August 2025 | Allow | 48 | 2 | 0 | Yes | No |
| 17430060 | TRIAMTERENE OR NOLATREXED FOR USE IN THE TREATMENT OF PHENYLKETONURIA | August 2021 | December 2024 | Allow | 40 | 1 | 0 | No | No |
| 17430240 | COMPOSITIONS COMPRISING AMINO ACIDS FOR USE AND TREATMENT OF CENTRAL NERVOUS SYSTEM INJURIES | August 2021 | October 2025 | Allow | 50 | 4 | 0 | Yes | No |
| 17429575 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF ACIDOSIS | August 2021 | May 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17428917 | METHODS FOR TREATING CUTANEOUS AGING | August 2021 | January 2026 | Abandon | 54 | 2 | 0 | No | Yes |
| 17310181 | CANNABIDIOL AND/OR DERIVATIVES THEREOF FOR USE IN THE TREATMENT OF MITOCHONDRIAL DISEASES | July 2021 | April 2025 | Allow | 45 | 2 | 0 | No | No |
| 17421741 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | July 2021 | April 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17415085 | AGENT FOR IMPROVING INFERTILITY, RECURRENT MISCARRIAGE, AND STATE OF PREGNANCY | June 2021 | June 2025 | Abandon | 48 | 2 | 0 | No | No |
| 17414404 | ORAL THERAPY USING 6,8-BIS-BENZYLTHIO-OCTANOIC ACID | June 2021 | June 2025 | Abandon | 48 | 2 | 0 | No | No |
| 17413346 | METHOD FOR PRODUCING REFINED PRODUCT OF PEAR JUICE | June 2021 | February 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17312898 | STABLE FORMULATIONS OF ANESTHETICS AND ASSOCIATED DOSAGE FORMS | June 2021 | November 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17344830 | KINASE INHIBITORS AND METHODS OF USE THEREOF | June 2021 | April 2025 | Allow | 46 | 2 | 1 | Yes | No |
| 17341817 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | June 2021 | September 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17341158 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | June 2021 | October 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17340082 | BICYCLIC SULFONES AND SULFOXIDES AND METHODS OF USE THEREOF | June 2021 | February 2025 | Allow | 44 | 1 | 1 | No | No |
| 17298198 | ELACESTRANT IN COMBINATION WITH ABEMACICLIB IN WOMEN WITH BREAST CANCER | May 2021 | June 2025 | Abandon | 48 | 2 | 0 | No | No |
| 17294353 | INHIBITORS OF ARG1 AND/OR ARG2 | May 2021 | October 2024 | Allow | 41 | 1 | 0 | No | No |
| 17292677 | MICROMOLECULAR COMPOUND SPECIFICALLYDEGRADING TAU PROTEIN, AND APPLICATION THEREOF | May 2021 | October 2024 | Allow | 41 | 1 | 0 | No | No |
| 17292511 | SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | May 2021 | May 2025 | Allow | 48 | 1 | 1 | Yes | No |
| 17292480 | COMBINATION OF A MCL-1 INHIBITOR AND MIDOSTAURIN, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | May 2021 | November 2024 | Abandon | 43 | 1 | 1 | No | No |
| 17292528 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | May 2021 | March 2025 | Allow | 46 | 2 | 1 | No | No |
| 17313885 | EPINEPHRINE SPRAY FORMULATIONS | May 2021 | January 2025 | Allow | 44 | 1 | 0 | Yes | No |
| 17245240 | GASTRIC CANCER TREATMENTS | April 2021 | September 2024 | Abandon | 41 | 1 | 1 | No | No |
| 17289406 | TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR | April 2021 | February 2025 | Allow | 45 | 2 | 1 | No | No |
| 17288063 | UPADACITINIB CRYSTAL FORM AND PREPARATION METHOD THEREFOR AND USE THEREOF | April 2021 | August 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17286904 | PPAR delta ACTIVATOR | April 2021 | December 2024 | Allow | 44 | 2 | 0 | No | No |
| 17286932 | SYNTHESIS OUTSIDE HIGH AND LOW TEMPERATURE EQUILIBRIUM BY SPRAY FLASH SYNTHESIS | April 2021 | November 2024 | Allow | 43 | 1 | 0 | Yes | No |
| 17285780 | PROCESS FOR PRODUCING ETHYLENE OXIDE BY GAS-PHASE OXIDATION OF ETHYLENE | April 2021 | August 2024 | Allow | 40 | 1 | 0 | No | No |
| 17231168 | Novel Phenyl Derivatives | April 2021 | October 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17285791 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | April 2021 | March 2026 | Allow | 59 | 4 | 1 | No | No |
| 17285414 | COMPOSITIONS AND METHODS FOR SUPPRESSING AND/OR TREATING A GROWTH RELATED DISEASE AND/OR A CLINICAL CONDITION THEREOF | April 2021 | August 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17285180 | COMPOUND AS TGF-beta R1 INHIBITOR AND APPLICATION THEREOF | April 2021 | July 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17229036 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | April 2021 | September 2024 | Abandon | 41 | 1 | 1 | No | No |
| 17224025 | SHP2 INHIBITOR COMPOSITIONS FOR USE IN TREATING CANCER | April 2021 | August 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17281745 | EGFR INHIBITORS FOR TREATING KERATODERMAS | March 2021 | August 2025 | Allow | 52 | 4 | 0 | No | No |
| 17280353 | 3-AZABICYCLO[3,1,1]HEPTANE DERIVATIVE AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | March 2021 | July 2024 | Allow | 39 | 1 | 0 | No | No |
| 17278017 | NOVEL SULFONAMIDE DERIVATIVE WITH FUSED PYRIMIDINE SKELETON, HAVING EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION INHIBITORY EFFECT | March 2021 | January 2025 | Allow | 46 | 2 | 1 | No | No |
| 17276459 | COMBINATION THERAPY FOR TREATING BLOOD CANCER | March 2021 | May 2024 | Allow | 38 | 1 | 0 | No | No |
| 17275604 | COMBINATION OF PARP INHIBITOR AND BRD4 INHIBITOR FOR THE TREATMENT OF CANCER | March 2021 | June 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17275450 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THERE OF | March 2021 | June 2024 | Allow | 40 | 1 | 1 | No | No |
| 17275462 | COMBINATION THERAPY FOR THE TREATMENT OF ESTROGEN-RECEPTOR POSITIVE BREAST CANCER | March 2021 | December 2025 | Abandon | 58 | 4 | 0 | Yes | No |
| 17274736 | NOVEL INHIBITORS OF GUANOSINE MONOPHOSPHATE SYNTHETASE AS THERAPEUTIC AGENTS | March 2021 | October 2024 | Allow | 44 | 1 | 1 | Yes | No |
| 17273646 | METHODS OF TREATING CYTOKINE RELEASE SYNDROME | March 2021 | June 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17268042 | BIOMARKERS FOR CANCER THERAPY | February 2021 | August 2024 | Allow | 42 | 1 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WILSON, JERICA KATLYNN.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner WILSON, JERICA KATLYNN works in Art Unit 1621 and has examined 63 patent applications in our dataset. With an allowance rate of 52.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 44 months.
Examiner WILSON, JERICA KATLYNN's allowance rate of 52.4% places them in the 14% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by WILSON, JERICA KATLYNN receive 1.35 office actions before reaching final disposition. This places the examiner in the 20% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by WILSON, JERICA KATLYNN is 44 months. This places the examiner in the 14% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +52.0% benefit to allowance rate for applications examined by WILSON, JERICA KATLYNN. This interview benefit is in the 94% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 38.2% of applications are subsequently allowed. This success rate is in the 87% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 62.5% of cases where such amendments are filed. This entry rate is in the 87% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants file petitions regarding this examiner's actions, 76.9% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 24.2% of allowed cases (in the 94% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.